We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $87.95 in the latest trading session, marking a +1.76% move from the prior day. This change outpaced the S&P 500's 0.22% loss on the day. Meanwhile, the Dow lost 0.66%, and the Nasdaq, a tech-heavy index, lost 0.22%.
Shares of the drugstore chain and pharmacy benefits manager have depreciated by 10.03% over the course of the past month, underperforming the Medical sector's loss of 4.73%, and the S&P 500's gain of 1.4%.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. The company is forecasted to report an EPS of $1.62, showcasing a 1.25% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $105.04 billion, showing a 2.11% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $8.02 per share and a revenue of $418.17 billion, representing changes of +18.81% and +4.01%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. CVS Health currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CVS Health currently has a Forward P/E ratio of 10.77. This represents a discount compared to its industry average Forward P/E of 17.01.
We can additionally observe that CVS currently boasts a PEG ratio of 0.84. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.62.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
CVS Health (CVS - Free Report) closed at $87.95 in the latest trading session, marking a +1.76% move from the prior day. This change outpaced the S&P 500's 0.22% loss on the day. Meanwhile, the Dow lost 0.66%, and the Nasdaq, a tech-heavy index, lost 0.22%.
Shares of the drugstore chain and pharmacy benefits manager have depreciated by 10.03% over the course of the past month, underperforming the Medical sector's loss of 4.73%, and the S&P 500's gain of 1.4%.
The investment community will be closely monitoring the performance of CVS Health in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. The company is forecasted to report an EPS of $1.62, showcasing a 1.25% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $105.04 billion, showing a 2.11% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $8.02 per share and a revenue of $418.17 billion, representing changes of +18.81% and +4.01%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CVS Health. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. CVS Health currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CVS Health currently has a Forward P/E ratio of 10.77. This represents a discount compared to its industry average Forward P/E of 17.01.
We can additionally observe that CVS currently boasts a PEG ratio of 0.84. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.62.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.